CSF hypocretin-1 assessment in sleep and neurological disorders (Q34593339)

3 August 2017

1 reference

title

CSF hypocretin-1 assessment in sleep and neurological disorders (English)

1 reference

3 August 2017

3

Emmanuel Mignot

1 reference

3 August 2017

1

Patrice Bourgin

1 reference

3 August 2017

Jamie M Zeitzer

2

1 reference

ORCID Public Data File 2021

language of work or name

1 reference

1 July 2008

1 reference

3 August 2017

1 reference

3 August 2017

7

1 reference

3 August 2017

7

1 reference

3 August 2017

649-662

1 reference

The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity

3 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Reduced number of hypocretin neurons in human narcolepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Orexin/hypocretin excites the histaminergic neurons of the tuberomammillary nucleus.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Excitation of ventral tegmental area dopaminergic and nondopaminergic neurons by orexins/hypocretins.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Hypocretin-1 modulates rapid eye movement sleep through activation of locus coeruleus neurons.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Roles of orexin/hypocretin in regulation of sleep/wakefulness and energy homeostasis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Hypocretin/Orexin: a molecular link between sleep, energy regulation, and pleasure

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Narcolepsy with cataplexy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Diagnosis of narcolepsy and idiopathic hypersomnia. An update based on the International classification of sleep disorders, 2nd edition

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Complex HLA-DR and -DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Hypocretin (orexin) deficiency in human narcolepsy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Genetic and familial aspects of narcolepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

The frustrating and mostly fruitless search for an autoimmune cause of narcolepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

CSF hypocretin/orexin levels in narcolepsy and other neurological conditions.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Hypocretin (orexin) levels in cerebrospinal fluid of patients with narcolepsy: relationship to cataplexy and HLA DQB1*0602 status.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

CSF hypocretin-1 levels in narcolepsy, Kleine-Levin syndrome, and other hypersomnias and neurological conditions

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Monozygotic twins concordant for narcolepsy-cataplexy without any detectable abnormality in the hypocretin (orexin) pathway.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

A monozygotic twin pair discordant for narcolepsy and CSF hypocretin-1.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Article reviewed: Plasma orexin-A is lower in patients with narcolepsy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Low cerebrospinal fluid hypocretin levels found in familial narcolepsy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

CSF hypocretin-1 (orexin-A) concentrations in narcolepsy with and without cataplexy and idiopathic hypersomnia.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

The narcoleptic borderland: a multimodal diagnostic approach including cerebrospinal fluid levels of hypocretin-1 (orexin A).

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

A study of the diagnostic utility of HLA typing, CSF hypocretin-1 measurements, and MSLT testing for the diagnosis of narcolepsy in 163 Korean patients with unexplained excessive daytime sleepiness.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Low CSF hypocretin-1/orexin-A associated with hypersomnia secondary to hypothalamic lesion in a case of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Narcolepsy without cataplexy: 2 subtypes based on CSF hypocretin-1/orexin-A findings.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Decreased cerebrospinal fluid hypocretin-1 levels near the onset of narcolepsy in 2 prepubertal children.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Follow-up of four narcolepsy patients treated with intravenous immunoglobulins

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Hypocretin deficiency in familial symptomatic narcolepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Undetectable CSF level of orexin A (hypocretin-1) in a HLA-DR2 negative patient with narcolepsy-cataplexy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

The prevalence of multiple sleep-onset REM periods in a population-based sample.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Correlates of sleep-onset REM periods during the Multiple Sleep Latency Test in community adults.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Difference in the characteristics of subjective and objective sleepiness between narcolepsy and essential hypersomnia.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Kleine-Levin syndrome: a systematic review of 186 cases in the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Kleine-Levin syndrome: a systematic study of 108 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Kleine-Levin syndrome: an autoimmune hypothesis based on clinical and genetic analyses

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Familial Kleine-Levin syndrome: two siblings with unusually long hypersomnic spells.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Kleine-Levin syndrome in a 14-year-old girl: CSF hypocretin-1 measurements.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

CSF hypocretin measures in patients with obstructive sleep apnea.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

A genetic risk factor for periodic limb movements in sleep

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

A step forward for restless legs syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Restless legs syndrome: a clinical update

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Bidirectional dopaminergic modulation of excitatory synaptic transmission in orexin neurons.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Direct involvement of orexinergic systems in the activation of the mesolimbic dopamine pathway and related behaviors induced by morphine.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Increased CSF hypocretin-1 (orexin-A) in restless legs syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

CSF hypocretin-1 levels in restless legs syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Narcolepsy associated with lesions of the diencephalon.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Symptomatic narcolepsy, cataplexy and hypersomnia, and their implications in the hypothalamic hypocretin/orexin system

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Isolated mediotegmental lesion causing narcolepsy and rapid eye movement sleep behaviour disorder: a case evidencing a common pathway in narcolepsy and rapid eye movement sleep behaviour disorder

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Narcolepsy and low CSF orexin (hypocretin) concentration after a diencephalic stroke.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

A hypersomnolent girl with decreased CSF hypocretin level after removal of a hypothalamic tumor

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Hypersomnolence and increased REM sleep with low cerebrospinal fluid hypocretin level in a patient after removal of craniopharyngioma.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Increased daytime somnolence despite normal sleep patterns in patients treated for nonfunctioning pituitary macroadenoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Acquired narcolepsy in an acromegalic patient who underwent pituitary irradiation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Sex and age at diagnosis are correlated with the HLA-DR2, DQ6 haplotype in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

CSF hypocretin (Orexin) in neurological and psychiatric conditions.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Hypersomnia and low CSF hypocretin-1 (orexin-A) concentration in a patient with multiple sclerosis showing bilateral hypothalamic lesions.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Hypocretin-1 CSF levels in anti-Ma2 associated encephalitis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Clinical analysis of anti-Ma2-associated encephalitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

CSF hypocretin levels in Guillain–Barré syndrome and other inflammatory neuropathies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Vivid dreams, hallucinations, psychosis and REM sleep in Guillain-Barré syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Cataplexy leading to the diagnosis of Niemann-Pick disease type C.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Sleep disturbances and hypocretin deficiency in Niemann-Pick disease type C.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Hypocretin Deficiency in Niemann-Pick Type C with Cataplexy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Niemann-Pick disease type C: cataplexy and hypocretin in cerebrospinal fluid

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Decreased Hypocretin-1 (Orexin-A) Levels in the Cerebrospinal Fluid of Patients with Myotonic Dystrophy and Excessive Daytime Sleepiness

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

The hypocretin neurotransmission system in myotonic dystrophy type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Normal hypocretin-1 levels in Parkinson's disease patients with excessive daytime sleepiness

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

CSF orexin levels of Parkinson's disease, dementia with Lewy bodies, progressive supranuclear palsy and corticobasal degeneration.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Parkinsonism with excessive daytime sleepiness--a narcolepsy-like disorder?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Parkinson's disease comorbid with narcolepsy presenting low CSF hypocretin/orexin level.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Low levels of ventricular CSF orexin/hypocretin in advanced PD.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Hypocretin (orexin) deficiency in narcolepsy and primary hypersomnia.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Rasmussen's syndrome and new-onset narcolepsy, cataplexy, and epilepsy in an adult.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Hypocretinergic dysfunction in neuromyelitis optica with coma-like episodes.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Hypersomnia and low cerebrospinal fluid hypocretin levels in acute disseminated encephalomyelitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Diagnostic aspects of narcolepsy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

A case of acute disseminated encephalomyelitis presenting hypersomnia with decreased hypocretin level in cerebrospinal fluid

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

CSF hypocretin-1 (orexin-A) levels in childhood narcolepsy and neurologic disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Hypocretin-1 (orexin-A) concentrations in cerebrospinal fluid are low in patients with Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

CSF hypocretin levels in Guillain-Barré syndrome and other inflammatory neuropathies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Hypersomnia after head-neck trauma: a medicolegal dilemma.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Hypocretin-1 (orexin A) deficiency in acute traumatic brain injury.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

CSF orexin-A/hypocretin-1 concentrations in patients with intracerebral hemorrhage (ICH).

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Sleep-wake disturbances 6 months after traumatic brain injury: a prospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Genetic factors in human sleep disorders with special reference to Norrie disease, Prader-Willi syndrome and Moebius syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Treatment of drop attacks in Coffin-Lowry syndrome with the use of sodium oxybate

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Narcolepsy in children

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Hypocretin deficiency in Prader-Willi syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

The number of hypothalamic hypocretin (orexin) neurons is not affected in Prader-Willi syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Parkinson's disease and sleepiness: an integral part of PD.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Hallucinations, REM sleep, and Parkinson's disease: a medical hypothesis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Development of diagnostic criteria for defining sleep disturbance in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

The effect of sleep-disordered breathing on stages of sleep in patients with Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Epidemiology and clinical features of sleep disorders in extrapyramidal disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Sleep and quantitative EEG in neurodegenerative disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Orexin loss in Huntington's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Hypothalamic-endocrine aspects in Huntington's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Hypocretin-1 (orexin A) levels are normal in Huntington's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Cerebrospinal fluid levels of orexin-A are not a clinically useful biomarker for Huntington disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

CSF hypocretin levels are normal in Huntington's disease patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Normal hypocretin-1 (orexin-A) levels in the cerebrospinal fluid of patients with Huntington's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Relationship between CSF hypocretin levels and hypocretin neuronal loss.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

The development of hypocretin (orexin) deficiency in hypocretin/ataxin-3 transgenic rats

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

The diurnal rhythm of hypocretin in young and old F344 rats

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

In Alzheimer disease, increased wake fragmentation found in those with lower hypocretin-1.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Hypocretin (orexin) loss in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Hypocretin (orexin) cell loss in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Normal CSF hypocretin-1 (orexin A) levels in dementia with Lewy bodies associated with excessive daytime sleepiness.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Cerebrospinal fluid hypocretin-1 levels in multiple system atrophy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Control of hypothalamic orexin neurons by acid and CO2.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Hypothalamus-brain stem circuitry responsible for vagal efferent signaling to the pancreas evoked by hypoglycemia in rat.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Ventricular cerebrospinal fluid hypocretin-1 inversely correlates with glucose levels in cerebrospinal fluid and serum from patients with neurological injuries

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

Transient total sleep loss in cerebral Whipple's disease: a longitudinal study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970140-6

7 January 2021

10.1016/S1474-4422(08)70140-6

Identifiers

DOI

1 reference

release_uzznstfrujaqnho4jeswhwt7zq

3 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/uzznstfrujaqnho4jeswhwt7zq

24 November 2022

mapped directly with Wikidata item

PubMed ID

18565458

1 reference

PubMed ID

18565458